After today’s close, we’ll get to see earnings out of Gilead Sciences Inc. (NASDAQ: GILD). The estimates for the biopharmaceutical company from First Call are $0.48 EPS on $1.22 billion in revenues. Next quarter…
If you thought biotech news was getting quiet going into earnings season, think again. Acadia Pharmaceuticals Inc. (ACAD) presents Phase II data on pimavanserin, a treatment for Parkinson’s disease psychosis (PDP) at the 60th…
Genentech, Inc. (NYSE:DNA) has announced that the biotech giant has authorized the extension of its current stock repurchase program through June 30, 2009 and it amended the current repurchase program. It is increasing the…
Alkermes (NASDAQ: ALKS) and Johnson & Johnson Pharmaceutical Research and Developed today submitted paperwork seeking approval of their partnership drug, RISPERDAL CONSTA, to be allowed for treatment of bipolar disorder chronic relapse. The drug…
Fluidigm, a California-based life science research device provider, has filed with the SEC to become public this morning. The offering shows a total proposed maximum aggregate price of $86,250,000. They applied to trade on…
Shares of Genentech Inc. (NYSE: DNA) are trading slightly lower after reporting a gain in earnings. The biotech giant posted $0.74 net EPS, but non-GAAP EPS excluding special items was $0.84 EPS on revenues…
The $8.8 Billion cash buyout of Millennium Pharmaceuticals, Inc. (NASDAQ: MLNM) has created a situation worth monitoring today. It isn’t just that this buyout could create a cascade of other biotech deals. The easier…
Millennium Pharmaceuticals Inc. (NASDAQ: MLNM) is being acquired. Takeda Pharmaceuticals in Japan is paying some $8.8 Billion to acquire the biotech, which had a market cap of $5.3 Billion as of yesterday. The cash…
Oncothyreon Inc. (NASDAQ: ONTY), a therapeutic cancer treatment biotech firm, announced today that the SEC has made their filing for periodic offering of up to $50,000,000 in securities effective. The offering was filed March…
Antigenics Inc. (NASDAQ: AGEN) has announced this morning that it has entered into definitive agreements to sell 7 million shares of its common stock at a price of $3.00 per share in a private…
Thursday after the close, we’ll get to see earnings out of Genentech (NASDAQ: DNA). The estimates from First Call are $0.82 EPS on $3.11 billion in revenues. Next quarter estimates are $0.86 EPS on…
AspenBio Pharma (NASDAQ: APPY) entered into a definitive agreement with Novartis Animal Health for AspenBio’s recombinant single-chain bovine products for animals. Shares are up 4% to $6.24. LifeCell (NASDAQ: LIFC)is to be bought by…
WuXi PharmaTech (Cayman) Inc. (NYSE: WX) has filed for a secondary offering of ADR’s in the US for 10,126,800 shares, or 11,645,820 if the overallotment option is used. The underwriting managers are listed as…
After looking through the filing and press release regarding Dendreon Corporation (NASDAQ: DNDN), there are some interesting data points that could be a game changer for current and future investors. The company raised roughly…
Medarex, Inc. (NASDAQ: MEDX) wants to clarify a few issues regarding the study halt from Pfizer (NYSE: PFE) this week on advanced melanoma. The company says that there are key differences between Pfizer’s discontinuing…